treating Disease Networks
Developing THERAPIES THAT TArGET AND PROTECT CELL NETWORKS
Oncology
TTX Founder Michael B. Sporn, MD spent over five decades committed to treating and preventing cancer. He set out to design compounds with the knowledge that inflammation and oxidative stress are unique and important drivers of carcinogenesis. TTX’s pipeline has broad potential to treat multiple cancers with the added capacity to lessen the toxic effects of chemotherapy and conventional radiation.
Other Chronic Diseases
Inflammation and oxidative stress are not only confined to cancers. They play a key role in the causation of neurodegenerative diseases. As proven brain penetrants, TTX compounds offer promising treatment for Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and Amyotrophic lateral sclerosis (ALS).
OUR DIFFERENCE
Nature
Oleanolic Acid is a triterpenoid compound widely found in plants and is an organic defense mechanism. Safely ingested for centuries, throughout history it has been believed to have healing properties. TTX has synthesized and modified Oleanolic Acid’s chemical structure to safely hyper accelerate and strengthen its true natural power.
Science
It took thirteen chemical steps and years of commitment to constant improvement to formulate the synthetic scaffold that TTX compounds are platformed on. FDA approved triterpenoid Omaveloxolone shares the CDDO scaffold that is the foundation of all TTX compounds. Our expanding pipeline is comprised of the latest and most powerful triterpenoids developed to date.
Innovation
TTX compounds are designed to treat disease comprehensively. They target cellular networks and tumor micro-environments through novel mechanisms of action that reduce inflammation and oxidative stress. They complement existing standards of care to overcome resistance providing immediate opportunity to positively impact patient outcomes.